The recent entry of biosimilar anti-TNFs into the European markets has attracted considerable attention—much of it centered on competitive discounting. Yet proprietary research with key payers and clinicians from 9 European countries shows that customer decisions are largely not based on price. Discover the initiatives that can incentivize these influential decision-makers and when to most effectively leverage each in the decision-making chain.
